Chemo-Immunotherapy: A New Trend in Cancer Treatment

1Chemotherapy has been the cornerstone of cancer treatment for over 70 years. In the last decade, ICIs have revolutionized cancer treatment, becoming the frontline therapy for many cancers. In some tumors, such as melanoma, renal cell carcinoma, and others, immunotherapy has largely replaced chemotherapy owing to its clinical benefits and toxic profile, and generally being more manageable and less severe than chemotherapy and radiotherapy. Nevertheless, despite this impressive clinical revolution, the rate of response to immune checkpoint blockade monotherapy is usually around 20% across solid tumors due to primary and acquired resistance to ICIs. The identification of novel biomarkers to discriminate the best responders and the combination of ICIs with other therapeutic modalities are promising avenues to improve their clinical response and patient outcomes.

2Cytotoxic chemotherapy has widely been regarded as immunosuppressive, since it causes dose-dependent myelosuppression, thereby suggesting an antagonistic effect with immunotherapy. Nevertheless, accumulated preclinical and clinical evidence has shown that certain chemotherapeutic drugs may act, under defined conditions, as strong adjuvants for enhancing antitumor immunity and, as a result, may potentiate immunotherapy. Accordingly, more than 200 clinical trials combining PD-1/PD-L1 blockade with chemotherapy have already been completed, and several chemo-immunotherapy combinations have recently been clinically approved owing to their improvement in patient survival, with generally expected safety profiles of the known toxicities of each agent. In this review, we discuss the mechanisms and conditions in which chemotherapy may stimulate antitumor immunity, and how this may be harnessed to improve the clinical effectiveness of ICIs.

3Immune checkpoints are crucial regulators of the activation of T cells that play a physiological role in preventing anti-self-responses and autoimmunity. In advanced cancers and chronic viral infections, chronic T cell stimulation induces and up-regulates the expression of inhibitory immune checkpoints, including Programmed Cell Death 1 (PD-1) and Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4), displaying an exhausted phenotype characterized by decreased proliferation, differentiation, and survival. T cell exhaustion limits unwanted immune responses in chronic viral infections, but hinders antitumor immunity in advanced cancers. Monoclonal antibodies targeting inhibitory immune checkpoints, including CTLA-4, PD-1, Programmed Cell Death 1 Ligand 1 (PD-L1), and Lymphocyte-Activation Gene 3 (LAG-3) capable of interfering with negative signals provided by these molecules have revolutionized cancer treatment. Despite their impressive clinical results, the rate of response to ICI monotherapies is far from being satisfactory, and a majority of patients with cancer have failed to exhibit clinical benefits from these therapies. Still, decades of chemotherapeutic treatment of cancer have shown that, with rare exceptions, single drugs targeting individual steps of carcinogenesis have demonstrated limited capability to cure due to the heterogeneity and complexity of advanced cancers. Combining different drugs and therapeutic modalities is an obvious strategy to improve patient outcomes.

4Cytotoxic drugs directly kill tumor cells and/or hinder their proliferation via multiple mechanisms including inducing DNA damage, inhibiting DNA replication, and/or preventing mitosis. Chemotherapeutic drugs in monotherapy have shown, with rare exceptions, limited efficacy; however, combination chemotherapy targeting multiple steps in carcinogenesis has been found to be a more effective strategy and, hence, has been widely extended and applied for cancer treatment. Combination regimens may provide a meaningful advantage over monotherapy, by maximizing cancer elimination within the range of tolerated toxicity, targeting a broader range of tumor cells with different genetic and epigenetic abnormalities among a heterogeneous tumor population, and also limiting or slowing the development of drug resistance.

5Conventional chemotherapy has a cytotoxic and cytostatic effect on healthy proliferating cells, especially on hematopoietic cells, causing myelosuppression. This suggests an antagonistic effect between chemotherapy and immunotherapy. In fact, some immunosuppressive drugs used to treat autoimmune diseases or to prevent transplant rejection are chemotherapeutics. Nevertheless, mounting evidence shows that the activation of host immunity decisively contributes to the efficacy of certain cytotoxic drugs; under defined conditions, they may display an immune stimulatory effect, providing an opportunity for their combination with immunotherapy. The rationale behind this combination lies in the fact that immunotherapy has the capability to eliminate disseminated and metastatic cancer, while it is less effective in eradicating a solid tumor mass. Chemotherapy may potentiate the efficacy of immunotherapy because it has the ability to debulk the primary tumor mass, decreasing the number of cells that should therefore need to be eliminated by immune cells, and also reducing the immunosuppressive factors produced by cancer cells. Additionally, certain chemotherapeutic drugs may directly stimulate antitumor immunity, which may be particularly relevant in “cold” tumors with low effector T cell infiltration within the tumor mass.

6Abundant preclinical evidence demonstrates that the efficacy of certain chemotherapeutic agents is higher in immunocompetent mice than in their immunodeficient counterparts. In good agreement, diverse studies have reported that common chemotherapeutic drugs may induce, in a dose- and schedule-dependent manner, antitumor immunity, mainly through the activation of effector T cells and NK cells and by specifically targeting the immunosuppressive tumor microenvironment (TME). In this section, we discuss the main immunomodulatory mechanisms underlying the action of chemotherapy (Figure 1).

7The type of cell death caused by cytotoxic chemotherapy is a determinant factor for triggering immunity or immune tolerance. Immunogenic cell death (ICD) is a modality of regulated cell death that results in cytotoxic lymphocytes (CTL)-mediated responses against antigens expressed by dying cells, ultimately triggering immunological memory (Figure 2). ICD is elicited by several cancer therapies, including radiotherapy and some chemotherapeutic drugs, such as anthracyclines, taxanes, cyclophosphamide, bortezomib, crizotinib, oxaliplatin, and other platinum-derivates (however, cisplatin is not a bona fide ICD-inducer). ICD is a potent endogenous immune adjuvant to the host innate immune system through the exposure and release of danger-associated molecular patterns (DAMPs) into the TME that are recognized by pattern recognition receptors expressed by antigen-presenting cells, mostly dendritic cells (DCs). Some DAMPs, including adenosine triphosphate (ATP) and annexin 1, enable the recruitment and chemotaxis of DCs; others, such as calreticulin, are exposed on the cell membrane acting as an “eat me signal” for the engulfment of the dying cell by DCs. The release of high-mobility group protein B1 (HMGB1) and the secretion of multiple cytokines, including type I interferons, culminates in the maturation of the DCs and the recruitment and activation of the CD8 T cell-mediated immune response against the tumor cells. This cascade of events promotes immune cell infiltration, shifting the tumors from “cold” to “hot” phenotypes.

8Growing preclinical evidence has shown that the immune stimulatory potential of ICD-induced drugs may be harnessed to improve the efficacy of the PD-1/PD-L1 blockade. In patients with HER2-negative unresectable gastric and gastro-esophageal junction adenocarcinomas, the combination of oxaliplatin-based chemotherapy with nivolumab significantly improved patients’ survival. Adding trastuzumab and chemotherapy (5-fluorouracil and cisplatin or capecitabine and oxaliplatin) to the PD-1 blockade resulted in a significant improvement in the objective response rate (ORR) (from 51.9% to 74.4%) in unresectable or metastatic HER2+ gastric or gastro-esophageal junction adenocarcinoma. The majority of metastatic triple-negative breast cancer (TNBC) patients showed no benefit from a PD-1/PD-L1 blockade in a phase II clinical trial (TONIC). However, the combination of doxorubicin with nivolumab resulted in 35% ORR, which was superior to cisplatin plus nivolumab (23%). Interestingly, doxorubicin and cisplatin treatment induced the upregulation of genes involved in the T cell cytotoxicity pathway, thereby providing a link between the clinical activity of these agents and their capacity to regulate systemic immunity. Nevertheless, a direct consequence of the induction of ICD is the upregulation of PD-L1 expression in many cancers and in myeloid cells, thus exerting a negative immunomodulatory effect, and altogether providing another justification for their combination with a PD-1/PD-L1 blockade.

9Non-lethal stress elicited by certain cytotoxic drugs may also activate T cells and render tumors more susceptible to T cell killing. For instance, treatment with paclitaxel induced the infiltration of CTLs in a mouse model of ovarian cancer and patients with breast cancer, as well as 5-fluorouracil in a murine model of breast cancer and temozolomide in models of melanoma. Multiple cytotoxic drugs have been shown to enhance DC maturation and activation, antigen presentation, and T cell activation, mainly in vitro. Cisplatin and doxorubicin have been shown to sensitize the most resistant colon cancer cell lines to TRAIL-induced cell death, and cisplatin, doxorubicin, and paclitaxel sensitize tumor cells to CTLs by making tumor cells permeable to granzyme B in mice.

10Advanced cancers progressively accumulate immunosuppressive cells in their TME, mostly regulatory T (Treg) cells and myeloid-derived suppressor cells (MDSCs) that remain a major barrier hindering effective antitumor immunity. Low doses of several cytotoxic drugs can selectively deplete both circulating and tumor-infiltrating Tregs concomitantly, stimulating antitumor immunity (Figure 2). Interestingly, this effect is particularly well documented with low-dose cyclophosphamide. Mechanistically, Tregs lack the expression of cyclophosphamide-extruding transporter ABCB1, being more sensitive to cyclophosphamide than effector immune cells. It is worth mentioning that cyclophosphamide at a higher dose also induces ICD. Multiple chemotherapeutic agents, including cyclophosphamide, cisplatin, paclitaxel, 5-fluorouracil, gemcitabine, and doxorubicin, selectively eliminate MDSCs in multiple mouse tumor models, resulting in immune recovery and tumor regression. However, recent reports suggest that, under certain conditions, chemotherapy might also induce the accumulation of MDSCs in TME. For example, certain cytotoxic drugs such as cyclophosphamide and melphalan may cause an increase in MDSC infiltration due to the inflammatory response triggered by chemotherapy. Thus, the effects of chemotherapy on MDSCs can vary depending on several factors, including the chemotherapeutic agent, dosage, and timing. Nevertheless, the clinical relevance of this preclinical evidence in cancer patients remains to be established.

11NK cells are cytotoxic innate immune cells that play a relevant role in cancer immunosurveillance and immunotherapy, particularly in hematological cancers and metastasis. NK cells can eliminate malignant tumors in a non-MHC and non-tumor antigen-restricted manner through an array of activating (i.e., NKG2D, DNAM-1, NCRs) and inhibitory receptors (i.e., KIRs, NKG2A-CD94) that detect changes in the expression of their ligands during viral infection and malignant transformation. Mounting preclinical evidence shows that the DNA damage response pathway initiated by ATM, ATR, and p53, induced by multiple genotoxic drugs, triggers tumor cells to express ligands for the NKG2D receptor. This upregulation promotes NK cell-mediated cytotoxicity and IFN-γ release, which subsequently favors the upregulation of MHC class I molecules on tumor cells, sensitizing them to CTLs (Figure 1). Similarly, hyperdiploid-inducing chemotherapeutic agents, including cytochalasin D, nocodazole, and docetaxel, strongly upregulate the tumor expression of NKG2D and DNAM-1 ligands, rendering tumor cells more susceptible to NK cell-mediated lysis. In patients with lung cancer, low-dose gemcitabine enhanced NK cell-mediated cytotoxicity, and a maintained administration of low-dose cyclophosphamide, referred to as metronomic dose (see Glossary), enhanced NK cell activity in end-stage cancer patients.

12PD-1 is not expressed in peripheral blood NK cells from most healthy individuals; however, in the context of cancer, its expression is induced in peripheral and tumor-derived NK cells, dampening antitumor immunity, which has been correlated with poor prognosis in multiple cancer patients. Interestingly, the response to PD-1 blockade may be enhanced by the increased number and activation of NK cells, thereby improving the clinical effectiveness, particularly in MHC class I-defective tumors. It is worth mentioning that some tumor cells can induce PD-L1 expression on NK cells via AKT signaling, and the PD-L1 blockade results in enhanced NK cell activity and tumor regression. This provides a potential explanation as to why some patients lacking PD-L1 expression in cancer cells still respond to anti-PD-L1 therapy. Collectively, accumulating evidence suggests a relevant contribution of NK cells to the clinical success of ICIs and, in this scenario, chemotherapy may improve their effectiveness through the activation of this immune subset.

13Chemotherapy drugs cause dose-dependent myelosuppression and, in the clinic, are usually administered at the maximum tolerated dose causing immunosuppression. Despite variable clinical results, metronomic chemotherapy is a promising alternative to the conventional dosage that may have a beneficial effect on TME by inhibiting tumor angiogenesis and boosting antitumor immunity, while avoiding toxicity caused by maximum-tolerated dose treatments. The underlying mechanism is far from being elucidated, but maximum tolerated dose regimens are associated with a depletion of effector immune cells, including CD4 and CD8 T cells, NK cells, and γδT cells, whereas low-dose regimens selectively target immunosuppressive Tregs and MDSCs, ameliorate T cell exhaustion, promote the maturation and activation of DCs, and concomitantly activate the NK and T cell-mediated antitumor immunity. Standard regimens, but not metronomic doses of temozolomide or paclitaxel, have abrogated the survival advantage provided by a PD-1 blockade in murine glioma and TNBC models, respectively. Metronomic gemcitabine in models of non-small-cell lung carcinoma (NSCLC) and low-dose cyclophosphamide in neuroblastoma have led to the increased efficacy and diminished toxicity of the PD-1 blockade due to reduced tumor angiogenesis dampening Tregs and enhancing the T cell effector response. Along these lines, metronomic oxaliplatin and pemetrexed together with a PD-1 blockade have successfully activated T cell immunity, eliciting tumor-specific long-term immune memory in colon cancer models. Similar results have been reported for combined metronomic chemotherapy with a multi-peptide vaccine and anti-PD-1 checkpoint inhibition in melanoma in vivo. These preclinical data suggest that the balance between active antitumor immunity and tumor elimination with less toxicity could be critical for the success of chemo-immunotherapy. In clinical settings, chemotherapy is conventionally administered at a maximum tolerated dose, and the effect of metronomic chemotherapy has not yet been well-established. This is particularly true for older patients, who are under-represented in current standardized clinical trials, and in whom a metronomic dose may ameliorate its adverse effects.

14TME is a key determinant of ICI responsiveness, and dynamically changes alongside tumor progression. A pronounced synergistic effect between immunotherapy and chemotherapy may be achieved in mouse models wherein the immune system of the mice is intact. Nevertheless, current ICIs are usually administered to patients with advanced cancer, who exhibit a deteriorated immune system due to immunoediting and chemotherapy treatment. Theoretically, immunotherapy administered to patients in earlier stages of the disease, with less deteriorated immunity and before a myeloablative chemotherapy treatment, would be more likely to cause a durable immunity than that caused by most current regimens. Likewise, first-line durvalumab in combination with etoposide plus platinum in treatment-naïve early-stage small-cell lung cancer (SCLC) showed an improvement in overall survival (OS) compared with chemotherapy alone. A recent meta-analysis based on 12 phase-III clinical trials with 9236 metastatic NSCLC patients reported that the addition of chemotherapy to ICIs enhanced their treatment efficacy as a first-line treatment. Nevertheless, this approach could have the disadvantage of exposing patients who would have responded to monotherapy to unnecessary toxicity.

15Chemotherapy and immunotherapy are administered concurrently in the vast majority of clinical trials. Still, the sequence of their administration may meaningfully affect outcomes. For instance, ipilimumab (anti-CTLA-4 antibody) administered after carboplatin and paclitaxel (but not concurrent administration) is associated with improved immune-related progression-free survival (PFS) in SCLC compared with chemotherapy alone. By contrast, patients with metastatic melanoma who progress after PD-1 therapy benefit from the subsequent addition of chemotherapy. Therefore, a rational timing selection is susceptible to becoming a cornerstone of chemo-immunotherapy success; intuitively, immunotherapy is more likely to work when administered before myeloablative chemotherapy regimens. Contrarily, non-myeloablative chemotherapy using drugs with immune stimulatory properties (i.e., causing ICD or a metronomic dose) are more likely to work before immunotherapy. Of note, doxorubicin and oxaliplatin, which are particularly efficient in promoting immune responses, are promising partners for administration before chemotherapy. Enhancing lymphocyte recovery using immunomodulatory drugs or cytokines or minimizing chemotherapy-induced damage to the immune system may potentiate ICIs, and may be an alternative to a maximum tolerated dose of chemotherapy currently used in clinical practice. Unfortunately, few clinical trials have tried to systematically identify the optimal conditions for chemo-immunotherapy, and no consensus has yet been achieved regarding the right dose, timing, and sequence of chemo-immunotherapy combinations that may maximize their clinical benefits.

16Combining ICIs with standard-of-care chemotherapy has been successful in the treatment of several tumors, particularly in some difficult-to-treat cancers with limited risks of overlapping toxicities between individual drugs (Table 1). The first and foremost success of chemo-immunotherapy has been achieved in lung cancer. Unprecedented efficacy was observed with the addition of standard chemotherapy to a PD-1 blockade with pembrolizumab, reducing the risk of death by half compared to chemotherapy alone in non-squamous NSCLC (OS at 12 months 69.2% vs. 49.4%), and in squamous NSCLC regardless of tumor PD-L1 expression status (OS 15.9 vs. 11.3 months). A combination of chemotherapy with the anti-PD-L1 antibody atezolizumab or anti-PD-1 antibody nivolumab plus ipilimumab also improved patient survival in NSCLC. Notably, neoadjuvant nivolumab combined with chemotherapy resulted in a significant improvement in event-free survival (EFS) and a pathological complete response (CR) in patients with resectable NSCLC (24% vs. 2.2%), suggesting that immunotherapy before surgery may enhance antitumor T cell immunity, favoring the rejection of micro-metastases after surgical resection. In SCLC, the addition of standard platinum to the PD-L1 blockade with atezolizumab or durvalumab yielded better results than chemotherapy alone (atezolizumab OS 12.3 vs. 10.3 months; durvalumab OS 13 vs. 10.3 months).

17TNBC is the breast cancer subtype with the poorest prognosis. However, it is more frequently infiltrated by tumor-infiltrating lymphocytes and more frequently expresses PD-L1 than other subtypes, thus suggesting that ICIs may be a promising therapy for TNBC. In patients expressing PD-L1 with a combined positive score (CPS) ≥ 10, pembrolizumab in combination with chemotherapy significantly reduced the risk of progression or death by 35% (PFS 9.7 vs. 5.6 months), leading to FDA approval. In early-stage TNBC, pembrolizumab added to neoadjuvant chemotherapy displayed a superior therapeutic efficacy compared to chemotherapy alone. Similarly, atezolizumab in combination with nab-paclitaxel showed superior clinical effectiveness and was approved for PD-L1+ metastatic TNBC.

18The conventional first-line treatment in head and neck squamous cell carcinomas (HNSCC) involves the combination of chemotherapy and the anti-EGFR antibody cetuximab. However, the combination of pembrolizumab with chemotherapy displayed superior efficacy to cetuximab plus chemotherapy, and it has been approved for the first-line treatment of patients with metastatic or recurrent HNSCC. Multiple clinical trials have demonstrated the efficacy of chemo-immunotherapy in digestive tumors (Table 1). For instance, pembrolizumab plus 5-fluorouracil and cisplatin reduced the risk of disease progression or death by 35% in patients with locally advanced or metastatic esophageal or gastroesophageal junction carcinoma. Nivolumab plus chemotherapy showed superior efficacy compared to chemotherapy alone, and was approved for first-time treatment for advanced gastric, gastroesophageal junction, or esophageal adenocarcinomas, and patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, regardless of PD-L1 status. An OS benefit was observed in patients with metastatic urothelial carcinoma who had completed platinum-based chemotherapy without disease progression and were subsequently maintained with the PD-L1 antibody avelumab (21.1 vs. 14.3 months). Chemo-immunotherapy combinations were also approved in advanced biliary tract cancer, and in cervical cancer (Table 1). Nevertheless, chemo-immunotherapy has not been a panacea for all tumors. Unfortunately, despite this aforementioned remarkable success, clinical studies have not been followed by a deep mechanistic analysis or the identification of predictive biomarkers. This means that it is likely that the drug combinations, the dose, the sequence, and the timing were not optimal in most clinical trials, and it is likely that a certain degree of immune cell toxicity and a lack of synergism hindered the efficacy of the combination of chemotherapy and ICIs.

19Several chemo-immunotherapy combinations have been successful in the treatment of multiple cancers, showing that chemotherapy can stimulate antitumor immunity and potentiate the clinical activity of ICIs. Nevertheless, hundreds of clinical trials have been completed, but only a few of them have succeeded. The development of fruitful chemo-immunotherapy combinations is constrained by our limited understanding of the immunomodulatory properties of chemotherapeutic drugs, and the optimal dose, timing, and sequence of chemo-immunotherapy combinations needed to tip the balance from immunosuppression to immune stimulation. To move forward, these issues should be re-examined in preclinical models and specific clinical trials, where cutting-edge technologies such as spatial transcriptomics and single-cell sequencing hold tremendous potential for advancing our understanding of the TME and its role in immunotherapy. Spatial transcriptomics allows the mapping of gene expression patterns within intact tissue samples, enabling the identification of different cell types and their interactions within the TME. Single-cell sequencing provides insights into the heterogeneity of individual cells, facilitating the characterization of immune cell subsets and their functional states. Integrating these technologies might provide novel insights into the complex interplay between tumor cells, immune cells, and stromal components in the TME in response to chemotherapy, leading to the identification of novel therapeutic targets and biomarkers for ICIs-based therapies. This deeper understanding has the potential to enhance treatment strategies, personalize therapies, and improve patient outcomes in the future. A major challenge in immunotherapy is in improving the preclinical models that may allow the rapid implementation of chemo-immunotherapy advances in clinical settings. The identification of novel biomarkers to predict the candidates who will obtain the greatest benefit from chemo-immunotherapy combinations is also essential. Despite these limitations, the increasing number of ICIs and the vast options for chemo-immunotherapy combinations for different types of cancers suggest an explosion of novel strategies for cancer therapy in the next few years.